Securities code: 002755 securities abbreviation: Beijing Aosaikang Pharmaceutical Co.Ltd(002755) Announcement No.: 2022-004
Beijing Aosaikang Pharmaceutical Co.Ltd(002755)
Independent opinions of independent directors on matters related to the 18th meeting of the 5th board of directors of the company
In accordance with the guiding opinions on the establishment of independent director system in listed companies, the guidelines for the governance of listed companies, the articles of association and the working system of independent directors and other relevant provisions, as independent directors of the company, we have checked the relevant materials with a serious, responsible and independent judgment attitude, and after careful analysis, We hereby express the following independent opinions on the relevant matters of the 18th meeting of the Fifth Board of directors of the company:
1、 Independent opinions on the general election of the board of directors and the nomination of members (non independent directors) of the sixth board of directors of the company
As an independent director of Beijing Aosaikang Pharmaceutical Co.Ltd(002755) (hereinafter referred to as “the company”), we have carefully reviewed the relevant materials provided by the company in accordance with the relevant provisions of the guiding opinions on the establishment of independent director system in listed companies, the stock listing rules of Shenzhen Stock Exchange and the guidelines for the standardized operation of listed companies of Shenzhen Stock Exchange issued by the CSRC, Based on his own independent judgment, he expressed the following independent opinions on the general election of non independent directors of the company’s board of directors:
We believe that the six non independent directors nominated by the board of directors of the company this time have the qualifications and work experience to perform the duties of directors, are competent for the duties of the positions they are employed, and are qualified to serve as directors of the company. There are no circumstances stipulated in the company law, the guidelines for the standardized operation of listed companies of Shenzhen Stock Exchange and the articles of association that they are not allowed to serve as directors of the company, have not been punished by the CSRC and other relevant departments and the stock exchange, and are not “dishonest Executees” or state civil servants.
To sum up, we agree that the board of directors of the company nominates Mr. Chen Qingcai, Ms. Wang Xiaowen, Ms. Zhou suling, Mr. Ma Jingfei, Mr. Xu Youyin and Mr. Chen Xiangfeng as candidates for non independent directors of the sixth board of directors of the company. The proposal needs to be submitted to the general meeting of shareholders of the company for deliberation.
2、 Independent opinions on the general election of the board of directors and the nomination of members (independent directors) of the sixth board of directors of the company
After verification, we believe that the three independent directors nominated by the board of directors of the company have the qualifications and work experience to perform their duties as directors, are competent for the job requirements of their positions, and are qualified to serve as independent directors of the company. It is not found that the company law, the measures for the filing of independent directors of Shenzhen Stock Exchange, the guidelines for the standardized operation of listed companies of Shenzhen Stock Exchange and the articles of association stipulate that they are not allowed to serve as directors and independent directors, and have not been punished by the CSRC and other relevant departments and the stock exchange, There is no case that more than five listed companies concurrently serve as independent directors, which does not belong to “dishonest Executees”, national civil servants and securities analysts. All candidates for independent directors have obtained the qualification certificate of independent directors recognized by Shenzhen Stock Exchange, have the independence that independent directors must have and the qualifications and conditions for serving as independent directors of the company, and comply with relevant regulations.
To sum up, we agree that the board of directors of the company nominates Mr. Wu Xiaoming, Mr. Li Di and Mr. Liu Jianwen as independent director candidates of the sixth board of directors of the company, and agree to submit the proposal to the general meeting of shareholders of the company for deliberation after the independent director candidates are reviewed and approved by Shenzhen Stock Exchange.
(there is no text below, which is the signature page)
(there is no text on this page, which is the signature page of Beijing Aosaikang Pharmaceutical Co.Ltd(002755) independent directors’ independent opinions on matters related to the 18th meeting of the Fifth Board of directors of the company) independent directors:
Wu Xiaoming, Li Di, Liu Jianwen
January 21, 2022
